Pharma Pricing Law: Minnesota Defeat
The Minnesota prescription drug pricing law faces a major setback as a U.S.appeals court blocks the state’s openness efforts. This decisive court ruling, fueled by a lawsuit from the pharmaceutical industry, halts a law designed to shed light on the factors behind rising medication costs. The Minnesota law, similar to those in other states, sought to uncover the expenses, revenue, and profits of pharmaceutical manufacturers, aiming to give consumers greater insight. News Directory 3 reports the Association for Accessible Medicines spearheaded the legal challenge, arguing the law overstepped state boundaries.With this crucial legal hurdle,how will this impact other states’ similar initiatives? Discover what’s next.
Court Halts Minnesota Drug Price Transparency Law
Updated June 13, 2025
A U.S. appeals court has upheld a previous ruling to stop a Minnesota law designed to increase transparency in prescription drug pricing, handing a victory to the pharmaceutical industry. The Association for Accessible Medicines initiated the lawsuit three years prior.
The association argued that the Minnesota law, enacted in 2020, oversteps state boundaries by regulating interstate commerce and applying to prices set in other states. The group also claimed the law violates due process rights because Minnesota coudl file lawsuits regarding transactions occurring outside of the state.
Minnesota’s law is similar to other transparency laws pursued in various states over the last decade. It seeks to pinpoint the elements that drive prescription drug costs higher, linking them to expenses, revenue, and profits reported by pharmaceutical manufacturers. The prescription drug pricing law aimed to provide greater insight into the factors influencing medication costs.
what’s next
The future of prescription drug pricing transparency laws in other states remains uncertain following this ruling. Further legal challenges to similar laws could emerge.